Business
CANTAB Mobile - submission for FDA clearance
CANTAB Mobile - submission for FDA clearance.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 2874X Cambridge Cognition Holdings PLC 05 May 2016 \n\n05 May 2016\nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\n \nCambridge Cognition submits CANTAB Mobile for FDA clearance\n \nThe neuroscience technology company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG) has made a submission in respect of its CANTAB Mobile product to the Food and Drug Administration ('FDA') in the USA for 510(k) clearance as a medical device for use within an American healthcare market estimated to be worth in excess of $110 billion1.\nThe CANTAB Mobile product was developed to detect episodic memory impairments in early stage Alzheimer's disease patients aged over 50. Since its launch the product has been used to assess over 25,000 people in the UK since being classified as a European Class IIa Medical Device in 2013.\nHaving established a commercial team in the USA in 2015 to drive sales into its core Academic Research and Pharmaceutical Clinical Trials markets; the FDA submission marks the first step in broadening out the Company's healthcare technologies into the American market.\nToday, 5.3 million Americans are living with Alzheimer's. By 2050, it is estimated that up to 16 million will have the disease2. The direct cost of caring for Alzheimer's patients in the United States is estimated to be $226 billion with half of the costs borne by Medicare2.\nDespite the growing numbers of patients, it is estimated that fewer than 50% of Alzheimer's cases are recognised and documented in primary care3, something the scientists at Cambridge Cognition believe CANTAB Mobile could \n\nimprove.\nA series of independent studies has demonstrated that the memory assessment in CANTAB Mobile is sensitive to detecting the earliest signs of prodromal Alzheimer's disease up to three years before a clinical diagnosis (Swainson et al., 2001; Fowler et al., 2002; Blackwell et al., 2004). Such early detection could serve to maximize the potential therapeutic benefit of treatment, enhance patient quality of life and reduce the burden on residential and nursing care services.\nSteven Powell, Chief Executive Officer, Cambridge Cognition: \"Having demonstrated the clinical efficacy and feasibility of CANTAB Mobile within the UK National Health Service it is our intention to broaden the commercia...